Cannabics Pharmaceuticals receives Cannabinoid R&D lab certification in Israel

The stated goal of Cannabics Pharmaceuticals is to be one of the first and few companies in the world to commercialize indication specific and clinically tested cannabis-based medical products. In Accordance with this goal, Cannabics Pharmaceuticals is currently in advanced preparations for the launch of a series of rigorous and controlled clinical studies in leading medical centers in Israel where the Company’s R&D division is strategically located.

Their new cutting edge laboratory is designed to employ novel technologies for the development of innovative cannabinoid based therapies for a range of debilitating ailments.

Dr. Zohar Koren, CEO, stated, "The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20th century due to a total ban on this field of research. Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications."

The company is especially interested in the development of cannabinoid-based anti-Cancer therapies.

"The unique properties of active cannabinoids as tumor cell proliferation inhibitors and apoptosis inducers has been known for decades, however this field has never received the appropriate scientific attention it deserves as a potential source for anti-cancer therapies," commented Dr. Eyal Ballan, Chief Technology Officer. "Our new and expansive laboratory will enable us to perform our advanced research program in this field."